Germline Genetic Variants Shape Safety and Activity of CAR‑T Therapy
Functional experiments link an inherited STXBP2 change to stronger inflammatory responses, pointing to donor selection and engineered CAR‑T strategies that require larger validation.
Overview
- The peer‑reviewed study published Friday analyzed whole‑genome sequencing, biomarker and lab data from 236 lymphoma patients treated with axicabtagene ciloleucel to search for inherited factors tied to outcomes.
- Researchers identified STXBP2 variants that were more common in patients with severe inflammatory toxicities and showed in experiments that loss of STXBP2 increased cytokine release and activated macrophages.
- Variants in ADAMTSL3 were associated with reduced risk of treatment‑related toxicity, while PTPN22 variants correlated with stronger CAR‑T cell expansion, a feature linked to treatment effectiveness.
- Because autologous CAR‑T products carry a patient’s inherited genes, the findings raise the prospect of using germline genetics to pick safer donors for off‑the‑shelf cells or to guide targeted engineering of CAR‑T cells.
- Authors say the results are an initial step and they will test the signals in larger, more diverse cohorts and across other CAR‑T products before any clinical changes are made.